Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of March 2022. The report serves as a notification to the market regarding the Company's issued share capital and total voting rights as of February 28, 2022, in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
- Issued Share Capital: 5,388,754,858 Ordinary Shares of 25 pence each.
- Treasury Shares: 304,905,950 Ordinary Shares.
- Total Voting Rights: 5,083,848,908.
Material Changes
The filing text does not provide a prior comparable period or data to determine material changes in financial performance or capital structure.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or unusual items. The document is a statutory notification of share capital figures intended for shareholder calculation of notification thresholds.
Investor Verification Checklist
- Verify the total number of voting rights (5,083,848,908) against the latest 20-F annual report to confirm the denominator for disclosure threshold calculations.
- Confirm the number of shares held in Treasury (304,905,950) to understand the difference between issued capital and voting rights.
- Note that this filing contains no operational or financial performance data; refer to the most recent quarterly or annual earnings release for financial metrics.